Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 1, 1996, Pages 88-94

  Muckenschnabel, Ingo ^a   Bernhardt, Günther ^a   Spruß, Thilo ^a   Buschauer, Armin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Drug distribution; Hyaluronidase; Malignant melanoma; Melphalan

Indexed keywords

HYALURONIDASE; MELPHALAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; ION PAIR CHROMATOGRAPHY; KIDNEY; LIVER; MALE; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TESTIS; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DIVISION; CELL TRANSPLANTATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; HYALURONOGLUCOSAMINIDASE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MELANOMA, EXPERIMENTAL; MELPHALAN; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; SPECIFIC PATHOGEN-FREE ORGANISMS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0029918307     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050452     Document Type: Article

References (40)

1. Balch CM, Houghton AN, Peters LJ (1993) Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia, pp 1612-1661
2. Baumgartner G (ed) (1988) Hyaluronidase - eine wirksame Substanz in der Behandlung maligner Erkrankungen? Referate gehalten im Rahmen der 6. Arbeitstagung des Ludwig-Boltzmann-Instituts für Hämatologie und Leukämieforschung, Wien (11. bis 13. Februar 1988). Wien Klin Wochenschr 178 [Suppl]:1-23
3. Baumgartner G, Moritz A (eds) (1988) Hyaluronidase: Anwendung in der Onkologie. Springer, Wien Berlin Heidelberg New York
4. Baumgartner G, Fortelny A, Zänker KS, Kroczek (1988) Phase I study in chemoresistant loco-regional malignant disease with hyaluronidase. Regional Cancer Treat 1:55-58
5. Beckenlehner K, Bannke S, Spruß T, Bernhardt G, Schönenberger H, Schiess W (1992) Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J Cancer Res Clin Oncol 118:591-596
6. Behnke AR (1941/42) Fat content and composition of the body. Harvey Lect 37:198
7. Bosanquet AG (1985) Stability of melphalan solutions during preparation and storage. J Pharm Sci 74:348-351
8. Bosanquet AG, Gilby ED (1982) Measurement of plasma melphalan at therapeutic concentrations using isocratic high-performance liquid chromatography. J Chromatogr 232:345-354
9. Chang SY, Alberts DS, Melnick LR, Walson PD, Salmon SE (1978) High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 67:679-681
10. Colvin M, Chabner BA (1991) Alkylating agents. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principles and practice. Lippincott, Philadelphia, pp 276-313
11. Cooper EH, Forbes MA (1988) Serum hyaluronic acid levels in cancer. Br J Cancer 58:668-669
12. Czejka MJ, Jäger W, Schüller J (1990) Influence of hyaluronidase on the blood plasma levels of 5-fluorouracil in patients. Pharmazie 45:693-694
13. Decker M, Chiu ES, Dollbaum C, Moiin A, Hall J, Spendlove R, Longaker MT, Stern R (1989) Hyaluronic acid-stimulating activity in sera from the bovine fetus and from breast cancer patients. Cancer Res 49: 3499-3505
14. Earnshaw JS, Curtis CG, Powell GM, Dodgson KS, Olavesen AH, Gacesa P (1985) The fate of intravenously administered highly purified bovine testicular hyaluronidase (hyalosidase) in the rat. Biochem Pharmacol 34:2199-2203
15. Egan CM, Jones CR, McCluskey M (1981) Method for the measurement of melphalan in biological samples by high-performance liquid chormatography with fluorescence detection. J Chromatogr 224:338-342
16. Flora KP, Smith SL, Cradock JC (1979) Application of a simple high-performance liquid chromatographic method for the determination of melphalan in the presence of its hydrolysis products. J Chromatogr 177:91-97
17. Fortmeyer HP (1981) Thymusaplastische Maus (nu/nu), thymusaplastische Ratte (rnu/rnu): Haltung, Zucht, Versuchsmodelle. Paul Parey, Berlin
18. Hay RJ (1988) The seed stock concept and quality control for cell lines. Anal Biochem 171:225-237
19. Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271:42-49
20. Kohno N, Ohnuma T, Truog P (1994) Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality. J Cancer Res Clin Oncol 120:293-297
21. 14C-hyaluronidase. Enzymol Biol Clin. 9:361-368
22. Krementz ET, Ryan RF, Muchmore JH, Carter RD, Sutherland CM, Reed RJ (1992) Hyperthermic regional perfusion of melanoma of the limbs. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S (eds) Cutaneous melanoma, 2nd edn. Lippincott, Philadelphia, pp 403-426
23. Lehnert M, Liu R, Salmon SE (1989) Hyaluronidase (HYase) enhances drug toxicity on clusters colonies of P-388 cells in clonogenic assay. Proc Am Assoc Cancer Res 30: A 2286
24. Levick JR (1987) Flow through interstitium and other fibrous matrices. Q J Exp Physiol 72:409-438
25. Liu R, Cox J, Salmon S (1987) Hyaluronidase enhances the in vitro cytotoxicity of 5-fluorouracil. Ann Meet Tissue Culture Assoc In Vitro 23:A 10
26. Meyer T, Göhl J, Schmidt O, Spruß T, Christl C, Bernhardt G, Hohenberger W (1994) Preclinical studies concerning hyperthermic isolated limb perfusion (HILP) of malignant melanoma. Regional Cancer Treat 7:138-143
27. Muckenschnabel I (1994) HPLC-Untersuchungen zum Einfluß von Hyaluronidase auf die Anreicherung von Melphalan in Tumorzeilen. Diplomarbeit, Universität Regensburg
28. Newell DR, Gore ME (1991) Toxicity of alkylating agents: clinical characteristics and pharmacokinetic determinants. In: Powis G, Hacker MH (eds) The toxicity of anticancer drugs. Pergamon, New York, pp 44-62
29. Pawlowski A, Haberman HF, Menon IA (1979) The effects of hyaluronidase upon tumour formation in Balb/c mice painted with 7,12-dimethylbenz-(a) anthracene. Int J Cancer 23:105-109
30. Sargent NSE, Price JE, Tarin D (1983) Effect of enzymatic removal of cell surface constituents on metastatic colonisation potential of mouse mammary tumour cells. Br J Cancer 48:569-577
31. Scheithauer W, Temsch EM, Stefeneli T, Lathan B (1988) Ergebnisse experimenteller Untersuchungen des zytostatikamodulierenden Effektes von Hyaluronidase bei gastrointestinalen Karzinomzellinien. Wien Klin Wochenschr 178 [Suppl]:12-13
32. Schumer J, Klocker J, Tidstrand J, Rab B, Allmayer H (1990) Cis-Platin, Vindesin und Hyaluronidase in Kombination mit simultaner Strahlentherapie bei fortgeschrittenen Tumoren im Hals-Kopfbereich. Onkologie 13:310-312
33. Seipelt H, Kohlheb O (1967) Die Mitoseaktivität des EhrliehAscites-Carcinoms der weißen Maus nach intraperitoneulen Hyaluronidase-Gaben. Arzneimittelforschung 17:513-515
34. Sokal RR, Rohlf FJ (1987) Introduction to biostatistics. 2nd edn. Freeman, New York
35. Spruß T, Bernhardt G (1996) Chemosensitivity of malignant melanoma models: long-term complete remission after regional hyaluronidase vinblastine therapy. In: Arnold W (ed) Immunodeficient laboratory animals. (Contributions to Oncology series) Karger, Basel (in press)
36. Spruß T, Bernhardt G, Schönenberger H, Schiess W (1995) Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin Oncol 121:193-202
37. Spruß T, Schlemmer R, Bernhardt G, Wiesenmeyer F, Baumann O (1996) Five-year breeding data, immunology, and tumor take rates of a NMRI nude mouse colony. In: Arnold W (ed) Immunodeficient laboratory animals. (Contributions to Oncology series) Karger, Basel (in press)
38. Thompson JF, Gianoutsos MP (1992) Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16:227-233
39. Wieberdink J, Benckhuysen C, Braat RP, Slooten EA van, Olthuis GAA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and gradient of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905-910
40. Wolf RA, Chaung L-Y, O'Hara D, Smith TW, Muller JE (1982) The serum kinetics of bovine testicular hyaluronidase in dogs, rats and humans. J Pharmacol Exp Ther 222:331-337